The repair of articular cartilage is challenging due to the sparse native cell population combined with the avascular and aneural nature of the tissue. In recent years cartilage tissue engineering has shown great promise. As with all tissue engineering strategies, the possible therapeutic outcome is intimately linked with the used combination of cells, growth factors and biomaterials. However, the optimal combination has remained a controversial topic and no consensus has been reached. In consequence, much effort has been dedicated to further design, investigate and optimize cartilage repair strategies.
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Abstract.
The repair of articular cartilage is challenging due to the sparse native cell population combined with the avascular and aneural nature of the tissue. In recent years cartilage tissue engineering has shown great promise. As with all tissue engineering strategies, the possible therapeutic outcome is intimately linked with the used combination of cells, growth factors and biomaterials. However, the optimal combination has remained a controversial topic and no consensus has been reached. In consequence, much effort has been dedicated to further design, investigate and optimize cartilage repair strategies.
Specifically, various research groups have performed intensive investigations attempting to identify the single most optimal cell source for articular cartilage repair strategies.
However, recent findings indicate that not the heavily investigated mono cell source, but the less studied combinations of cell sources in co-culture might be more attractive for cartilage repair strategies. This review will give a comprehensive overview on the cell sources that have been investigated for articular cartilage repair strategies. In particular, the advantages and disadvantages of investigated cell sources are comprehensively discussed with emphasis on the potential of co-cultures in which benefits are combined while the disadvantages of single cell sources for cartilage repair are mitigated.
Introduction
Mature articular cartilage is composed of an abundant extracellular matrix that is sparsely populated by chondrocytes. Articular cartilage is avascular and aneural and the native chondrocytes are largely in cell cycle arrest. As a consequence, it is challenging for this tissue to suitably respond to traumatic injury. Cartilage damage inevitably results in altered biomechanics of the joint and joint instability, which shift joint homeostasis towards catabolism (1, 2) . If left untreated, this may ultimately lead to joint failure. As a result, the recalcitrant capacity of articular cartilage to self-heal acquired injuries drives research focused on (novel) cartilage reparative and regenerative treatments.
Current treatments of traumatic cartilage defects include osteochondral grafting, bone marrow stimulation techniques and more recently cell based therapies (3-6).
Osteochondral autografting is particularly suitable for smaller lesions, but is associated with donor-site morbidity (7) . Osteochondral allografting can be considered for larger defects, but is associated with graft failure and immune reactions (8, 9) . Bone marrow stimulation techniques such as micro-fracturing and micro-drilling are used for defects smaller than 2-4 cm 2 with little or no bone loss and are associated with the formation of fibrocartilage (10) . The most common form of cell-based therapies is autologous chondrocyte implantation (ACI). This treatment is based on the implantation of expanded autologous chondrocytes, which were isolated from a biopsy that was obtained from a non-load bearing site of the same donor. Since ACI is dependent on the violation of intact cartilage as well as ex-vivo chondrocyte expansion, it is associated with donor-site morbidity and loss of chondrogenicity of cultured chondrocytes known as dedifferentiation (4).
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Consequently, a myriad of alternative cell sources other than culture expanded articular chondrocytes have been investigated to circumvent these side-effects and thereby to improve the therapeutic outcome of cartilage repair strategies. In addition to several types of chondrocytes derived from a number of hyaline cartilage subtypes, the use of multi-potent cells with chondrogenic potential derived from various tissue sources has been proposed. In addition to conventional mono-culture the approach of co-cultures has gained significant attention. Interestingly, co-cultures have been shown to be able to outperform their respective single cultures. Unfortunately, in depth understanding and clinical translation of this phenomenon has remained wanted. This review will discuss the different cell sources dominating the field of cartilage tissue engineering and highlights recent advances of co-culture approaches.
Autologous articular chondrocytes: cell number versus dedifferentiation
Conventional cell-based cartilage repair therapies characteristically use autologous articular chondrocytes. These cells are harvested from biopsies of macroscopically intact cartilage derived from a non-weight bearing part of the joint (11).
Removal of a biopsy from healthy articular cartilage can potentially lead to secondary osteoarthritis. However, more thorough studies with a longer follow-up are required to understand the full extent of the consequences of harvesting biopsies (12). To minimize the chance of developing secondary osteoarthritis the biopsy size is limited. In consequence, the biopsy yields insufficient amounts of chondrocytes to allow for direct filling of the defect. Therefore, chondrocytes are expanded in vitro before reimplantation.
Unfortunately, expansion is associated with progressive loss of the chondrogenic phenotype and results in dedifferentiated fibroblast-like chondrocytes (13) . We recently 7 demonstrated that articular chondrocyte dedifferentiation is a continuous, progressive and multi-signaling-pathway-based process. Moreover, the potential to redifferentiate is also gradually lost and might be in part caused by epigenetic mechanisms such as DNA methylation. The loss of the chondrocyte phenotype during monolayer expansion is suggested to be dependent on the matrix elasticity of the culture environment (14) . As this process can impede the therapeutic outcome, the prevention of dedifferentiation and/or the induction of redifferentiation have been intensively investigated. Investigated strategies include exposure to optimized environmental properties like reduced oxygen levels (15) and physiological tonicity of the culture medium (16), dynamic non-adherent culturing as aggregates (17) (9), whereas on the other hand the protective environment of the native cartilage will limit immunological reactions. The avascular and highly dense nature of the extra cellular matrix might be able to limit or prevent the invasion of immune cells from the joint to interact with chondrocytes. Indeed, isolated chondrocytes appear to be protected from an immune response when encapsulated in biocompatible biomaterials or when allowed to form a new extracellular matrix in vitro (37, 38) . Due to their more wide availability and the limited immunogenic risk when embedded in an extracellular matrix, non-autologous articular chondrocytes can be still considered as a potentially interesting cell source for matrix assisted chondrocyte transplantations.
Non-articular chondrocytes: morbidity versus phenotype
Next to articular chondrocytes, several alternative chondrocyte sources have been investigated to design cartilage repair strategies that do not impose additional damage to the articular cartilage. In adults, other sources of (non-articular) hyaline cartilage are located in the nose, ribs, larynx, trachea and bronchi. In particular, costal and nasoseptal chondrocytes have been extensively investigated (29, [39] [40] [41] . Both costal and nasoseptal cartilage biopsies, respectively harvested from the ribcage or from the septum of the nose, grant a higher cell yield of chondrocytes. The proliferation rate of these chondrocytes is increased compared to articular chondrocytes (42). Although they both undergo dedifferentiation during expansion they appear more susceptible to redifferentiation (43, 44) . Moreover, transplantation of costal chondrocytes in full thickness defects results in the production of neocartilage (45) . Unfortunately, both costal and nasoseptal This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
chondrocytes are known for their ability to ossify when reimplanted (40, 46, 47) . The different anatomical location and function of costal and nasoseptal cartilage might underlie their limited potential to form articular cartilage. In particular, the mechanical loading in the articular cartilage is frequent and highly compressive, whereas costal and nasoseptal cartilage experiences at best low tensile loads.
Auricular chondrocytes derived from elastocartilage of the ear are as well considered as a possibly interesting cell source for cartilage repair strategies. Native and freshly isolated auricular chondrocytes typically express elastin. Although, upon in vitro culture the expression of elastin is gradually lost (41, 48) , it has been reported that the elastin expression can be regained when implanted in vivo (49) . Whether the expression of elastin will negatively influence the mechanical properties of neocartilage in an articular cartilage defect remains to be clarified. Like nasoseptal and costal cartilage, isolated auricular cartilage provides a higher cell yield per gram of biopsied tissue and have a higher proliferation rate compared to articular cartilage. Auricular chondrocytes are prone to dedifferentiation and are susceptible to redifferentiation (42, 50) . Mild forms of ossification have been observed after reimplantation (40) . Even though auricular cartilage has a rather non-loaded, supportive function for the external ear, it has been found that auricular chondrocytes express lubricin, a mucinous glycoprotein essential for lubrication of the joint (41) . Therefore, auricular chondrocytes are a cell source of considerable interest, in particular for repair or reconstruction of the superficial zone of articular cartilage.
Meniscal chondrocytes derived from the meniscal fibrocartilage also express lubricin and have been investigated in cartilage repair strategies (41, 51) . However, This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
meniscal chondrocytes scarcely express collagen II, and have limited potential to secrete glycosaminoglycans. Consequently they generate neocartilage with inferior mechanical properties as compared to articular cartilage or other chondrocyte cell sources (52) . Like ACI, the use of meniscal chondrocytes is based on cells isolated from a biopsy and may predispose to secondary OA, as it can induce joint instability (53) . Additionally, the meniscus is partially exposed to the same catabolic environment as the articular cartilage, which deteriorates the chondrogenic behavior of the meniscal chondrocyte (54). As meniscal chondrocytes have similar disadvantage compared to articular chondrocytes and produce inferior neocartilage compared to these cells, they are an unlikely cell source for articular cartilage repair strategies.
Taking all available alternative chondrocyte populations into consideration, it is obvious that none of the alternative chondrocyte sources are exposed to a mechanical challenge, which is comparable to the stimuli present in the articular joint. Nevertheless, chondrocytes from alternative sources surpass articular chondrocytes in availability, cell yield and proliferation capacity and might be suitable for patient groups where the access to articular chondrocytes is limited.
Non-chondrocyte cell sources: morbidity versus control of differentiation
Recently much research has been dedicated to cell sources other than articular chondrocytes. This is mainly due to articular chondrocyte's low availability and its limited expansion capability without loss of function. These alternative cell sources include amongst others synovial fibroblasts, periosteocytes and multipotent progenitor cells. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
Synovial fibroblasts are a part of the natural repair response to articular defects, as these cells tend to fill up non-treated defects with a fibrous matrix (55) . Unfortunately, this matrix is, like the matrix produced by meniscal chondrocytes, mechanically weak and predominantly consists of collagen type 1 (56) . Periosteocytes, depending on their site of isolation, possess chondrogenic potential that allows the formation of neocartilage (57). However, it has been suggested that this potential is inversely correlated with age.
(58). In general, synovial fibroblast and meniscal chondrocytes have shown less promise compared to pluripotent/multipotent progenitor cells as an non-chondrocyte cell source.
Pluripotent cells such as embryonic stem cells and induced-pluripotent stem cells are able to form de novo articular-like cartilage and can in theory be considered for cartilage repair strategies (59, 60) . However, gaining absolute control on the prevention of teratoma formation is paramount when using these cells (61, 62) . Until such control is acquired, it is unlikely that these cell sources will be clinically approved for treatment of non-lethal diseases such as articular cartilage repair.
The best characterized progenitor cell sources for articular cartilage repair include mesenchymal stromal cells (MSCs) derived amongst others from bone marrow, periosteum, synovium, synovial fluid, adipose tissue, bucal fat pad, infrapatellar fat pad and osteoarthritic cartilage (63) (64) (65) (66) (67) This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
accessibility, availability, age-related function decline, donor-site morbidity and acquisition costs.
Large inter-donor variation is a general complication encountered in all multipotent cell sources (76, 77) . This is exacerbated by the influence of temporal culture conditions, methods of harvest and disputably donor age (57, 78-81). It has been suggested that distinct gene expression profiles might reflect their (chondrogenic) differentiation potential (82) . However, the highly desired markers for chondrogenic differentiation potential of undifferentiated MSCs have so far remained undiscovered. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
engineering strategies. Presently much attention is paid towards optimizing physiological factors, which influence cell behavior and thus therapy outcome, such as mechanical stress, substrate stiffness, substrate coating or chemistry and incubator gas composition in particular oxygen levels (95) (96) (97) (98) (99) (100) (101) (102) (103) . Other physiological variables such as tonicity have remained largely uninvestigated.
Rather than using MSCs for chondrogenic differentiation and direct production of neocartilage, one can also take advantage of the immunomodulatory or trophic properties of MSCs (104) . It is suggested that after reimplantation differentiated MSCs continue to modulate the immune response (105) . This might be of high importance in allogeneic treatments (106) . However, whether this modulation proves to be sufficient in tissues that are scarce in cells and rich in matrix, such as articular cartilage, remains to be further studied. Nonetheless, using allogeneic strategies allow for a decrease in the therapeutic and FRZB. These secreted antagonists were proven to function as inhibitors of hypertrophic differentiation (116) . Consequently, chondrogenically differentiated multipotent and pluripotent cells undergo endochondral ossification upon subcutaneous implantation (60, 120) . Although this phenomenon is of notable interest for bone repair strategies, it is highly undesirable for cartilage repair strategies. Moreover, it demonstrates that current differentiation protocols, at least in vitro, are insufficient to yield articular-like cartilage and require improvement for reproducible cartilage repair strategies. Finally, it is of importance to note that the formation of functional neocartilage has been witnessed in orthotopic repair in animal models. This suggests that the joint microenvironment contains instructive stimuli for the formation of permanent articular cartilage (121) . This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. Although the mechanism behind this phenomenon remains largely unknown, some evidence suggests that this effect is mediated via parathyroid hormone-related protein (129) . However, alternative explanations such as articular cartilage derived factors inhibiting hypertrophic chondrocyte differentiation have remained uninvestigated (116) .
Co-cultures: combinatorial advantages versus current knowledge
The first studies in which MSCs were combined with other cell sources to provide a distinct effect included the vascularization of bone tissue engineered constructs (130, 131) and improvement of matrix deposition in degenerative discs (132) . In contrast, in cartilage repair strategies MSCs were initially used to reduce the amount of chondrocytes needed or to omit their use all together. Fascinatingly, chondro-induction was observed in these experiments; superior neocartilage was formed by the combination of two different This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
Alternative strategies to improve neocartilage formation using co-cultures include the generation of articular cartilage's zonal architecture ( Figure 1C ). In recent years novel cartilage repair strategies have been designed that aim at mimicking this anisotropic organization (138, 139) . Co-cultures in combination with multilayer three-dimensional printing or layer-by-layer methodology using hydrogels that are able to covalently link by residual reactive residues e.g. dextran-tyramine gels (140) (141) (142) (143) can further enhance these strategies. Calcifying cells, or their precursors, can be used for the deep zone, intensive extracellular matrix producing calcification resistant cells for the middle zone, and less intensive extracellular matrix producing and lubricin secreting cells for the superficial zone. Furthermore, for example, osteoblasts and chondrocytes can be co-cultured in different regions of a construct to allow the formation of an osteochondral interface (144, 145) . However, as only a scarce number of studies have been reported on such an approach, the feasibility remains to be determined.
Conclusion
The therapeutic outcome of cell-based therapies does not solely rely on the performance of the implanted cells. It also heavily relies on the expansion conditions and exogenous stimuli. In addition, functionalized biomaterials currently under development and which can be used as carriers for cell implantation, are expected to provide a platform for controlling cellular phenotype in the near future. Subsequently, these factors can result in dissimilar responses in different cell sources. In short, much research remains to be performed in order to identify the combinations leading to optimal clinical results. The wide range of cell sources available to cartilage tissue engineers grants an optimal starting point for future improvement of cartilage repair strategies. Specifically, 
